The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
Use the free app to connect, model, and visualize data with an easy-to-use report canvas and hundreds of visuals. Sign up for the Microsoft Fabric free trial to explore the full suite of ...
On this week’s podcast, we open with a refresher on the four antitrust claims being debated at the Google antitrust trial – the ad server, the ad network, the ad exchange and tying those products ...
The long and winding trail to reach a consensus on whether or not the Town of Renfrew will undertake the establishment of a new nature/walking trail system on ...